TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04046146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSpectral Imaging System
Description: Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
Study: NCT01822197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
Study: NCT01375023

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: daily radiation therapy for 10 days, total dose of 80 cGY

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
Study: NCT02255461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib isethionate
Description: Given PO
Study: NCT00616850

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free normal saline
Description: Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
Study: NCT02348528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04078776

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study
Study: NCT03553628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine, Propolis and Clove Oil mouthwash
Description: Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine, Propolis and Clove Oil mouthwash
Description: Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine HCL 0.12% mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine HCL 0.12% mouthwash
Study: NCT04473651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06479
Description: capsules, orally (Part A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06479
Description: capsules, orally (Part A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo - capsules, orally (Part A only)
Study: NCT03307668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaReSR-1S
Description: CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
Study: NCT03680274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
Study: NCT01533896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grow Nicely
Description: Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
Study: NCT01484015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime hydrochloride
Description: Given IV
Study: NCT02785822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hMG-HP
Description: Ovarian stimulation with hMG-HP (150 IU / day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hFSH-HP
Description: Ovarian stimulation with hFSH-HP (150 IU / day)
Study: NCT02853188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: venous thromboembolism
Study: NCT00729261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extubation
Description: Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continued intubation
Description: patients remain intubated until their Glasgow coma scores improve to greater than 8.
Study: NCT01879488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: technetium-99m - Diethylenetriaminepentaacetic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: technetium-99m - Diethylenetriaminepentaacetic acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating-mesh nebulizer
Study: NCT03680274

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
Study: NCT03343691

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening Population
Description: Blood samples taken from screening population

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Population
Description: Blood samples taken from Breast Cancer population
Study: NCT04125316

Intervention type: OTHER
Intervention: Observation, no intervention
Description: Observational study, no intervnetion
Study: NCT01879488

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating-mesh nebulizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gamma scintigraphy
Study: NCT01616186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: * Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)
Study: NCT01879488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gamma scintigraphy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative spirometry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative spirometry
Study: NCT02210949

Intervention type: DRUG
Group type: OTHER
Intervention: Erythropoietin subcutaneously and Iron intravenously
Description: Administration of Erythropoietin subcutaneously and administration of iron intravenously
Study: NCT00957918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
Study: NCT01616186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib monotherapy
Description: Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)
Study: NCT01813318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
Study: NCT00186082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotetan or Cefoxitin vs placebo
Description: Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefotetan or Cefoxitin vs placebo
Description: Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm.
Study: NCT02983305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-Mounted Display
Description: Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-Mounted Display
Description: Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
Study: NCT01896518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Study: NCT03111940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimisation of the result of intracoronary stenting according to specific algorithm
Study: NCT04390607

Intervention type: DIAGNOSTIC_TEST
Intervention: leukocyte esterase electrochemical assay
Description: A sample of blood drawn for routine standard of care laboratory assessments will be used to also test the new electrochemical assay. This is a validation study and the results of the electrochemical assay will not be used to treat patients
Study: NCT01813318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receiving placebo will be dosed similarly to the acamprosate group.
Study: NCT01552772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: 400 mg intramuscular injection of aripiprazole
Study: NCT01896518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobacco lozenge
Study: NCT01761123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-A1.1
Study: NCT02974738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
Study: NCT02961595

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Polio Vaccine (OPV)
Description: Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
Study: NCT02335229

Intervention type: DEVICE
Intervention: Axium DRG Neurostimulator
Description: Implantation with Axium DRG Neurostimulator
Study: NCT03504956

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac MRI
Description: MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac MRI
Description: MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.

Intervention type: DRUG
Group type: OTHER
Intervention: Contrast
Description: The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).

Intervention type: DRUG
Group type: OTHER
Intervention: Contrast
Description: The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).

Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.

Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
Study: NCT01301625

Intervention type: DEVICE
Intervention: MitraClip Implant
Description: Percutaneous mitral valve repair using MitraClip implant.
Study: NCT03077854

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Lung Avoidance Thoracic Radiotherapy
Description: * Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Thoracic Radiotherapy
Description: * Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions
Study: NCT01535872

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
Study: NCT01207219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Description: 3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
Study: NCT03093129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate
Description: Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
Study: NCT05354401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HHF
Description: HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HHF
Description: HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
Study: NCT03224169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly observed hand hygiene
Description: Directly observed hand hygiene to the residents and staff
Study: NCT00604175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
Study: NCT00412165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell Phone
Description: The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly access to interactive web site
Description: This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group
Description: The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
Study: NCT00895180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: olaratumab
Description: Given IV
Study: NCT00957918

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
Study: NCT02419664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTATOC PET
Description: The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
Study: NCT00895180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Given IV
Study: NCT03876730

Intervention type: OTHER
Intervention: ICF CP Core Set
Description: Core set
Study: NCT01703793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product 49778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product 10156

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (placebo)
Study: NCT03247439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Synthetic Cartilage Implant
Study: NCT04596150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2009
Description: Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
Study: NCT00604175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
Study: NCT04241081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia
Description: This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia
Description: This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
Study: NCT02044094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine and naloxone
Description: Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydromorphone
Description: Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen).